Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

114P - PD-L1 prevalence and association with clinical outcomes among metastatic renal cell carcinoma patients treated with targeted therapies

Date

17 Sep 2020

Session

E-Poster Display

Topics

Targeted Therapy

Tumour Site

Presenters

Frede Donskov

Citation

Annals of Oncology (2020) 31 (suppl_4): S274-S302. 10.1016/annonc/annonc266

Authors

F. Donskov1, C.A. Pinto2, R. Predoui2, F. Kong2, C. Fox2, J. Georgsen1, K. Skaarup3, R. Perini2, T. Steiniche1

Author affiliations

  • 1 Pathology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 2 Clinical Research, Merck & Co., Inc., 07033 - Kenilworth/US
  • 3 Oncology, MSD Danmark, Copenhagen/DK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 114P

Background

In KEYNOTE-427 (a single arm Phase 2 trial of pembrolizumab monotherapy in advanced renal cell carcinoma [aRCC] patients) there was an association of programmed death ligand 1 (PD-L1) expression, using combined positive score (CPS), and tumor response. There are limited data on the association of PD-L1 expression using CPS and outcomes in patients treated with non-immunotherapy (IO) based regimens.

Methods

PD-L1 expression and association with outcomes was evaluated in 255 advanced clear-cell RCC (ccRCC) patients treated with standard of care at Aarhus University Hospital between 2006 and 2016. PD-L1 expression was measured by immunohistochemistry in nephrectomy specimens with PD-L1+ defined as a CPS ≥1. PD-L1 association was evaluated with best overall response (% complete or partial response) defined by clinician assessment, and progression-free and overall survival (PFS, OS) calculated using time to event analyses. Multivariate modeling was used, adjusted for International mRCC Database Consortium (IMDC) score, age, and other covariates.

Results

Among the 255 aRCC patients, the majority received VEGF inhibitors (mainly sunitinib [44%], pazopanib [38%]), median age was 63 (range: 37-88) years, with 68% male, 45%/34% IMDC int./poor risk, 24% sarcomatoid differentiation, and 69% Fuhrman grade III/IV. Best overall response rate was 26% with median PFS of 11 months. Overall, 61% of patients were PD-L1+, with a significant association (p<0.05) of PD-L1 expression with increasing Fuhrman grade, sarcomatoid differentiation, necrosis, and increasing IMDC risk. There was no association of PD-L1 expression with response rate or PFS. A negative association (p=0.04) was observed with OS, with shorter median survival for PD-L1+ (14.5 months [95%CI 10.2, 18.3]) compared with PD-L1 (28.3 months [95%CI 20.5,35.2]) When excluding patients receiving IO therapy (6%), response and PFS did not change, but OS association was borderline significant after multivariate adjustment (p=0.1).

Conclusions

PD-L1 expression may be a negative prognostic factor among aRCC patients. There was no correlation of PD-L1 expression levels with response to VEGF inhibitors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

F. Donskov: Research grant/Funding (institution): MSD; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Ipsen. C.A. Pinto: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. R. Predoui: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. F. Kong: Full/Part-time employment: Merck & Co., Inc. C. Fox: Full/Part-time employment: Merck & Co., Inc. K. Skaarup: Full/Part-time employment: MSD. R. Perini: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. T. Steiniche: Research grant/Funding (institution): MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.